Skip to main content
. 2018 Dec 11;10(1):21–33. doi: 10.1007/s13300-018-0547-5

Fig. 2.

Fig. 2

Incidence of nausea and vomiting per week with iGlarLixi vs. iGlar in LixiLan-L (a) and vs. lixisenatide in LixiLan-O (b)